Fundación Pública Galega de Medicina Xenómica
Centro de investigación
Maastricht University Medical Centre
Maastricht, HolandaPublicacións en colaboración con investigadores/as de Maastricht University Medical Centre (35)
2023
-
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2
Human Mutation, Vol. 2023
-
Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data: dosimetry, acute and two years physician and patient-reported outcomes
Acta Oncologica, Vol. 62, Núm. 9, pp. 1036-1044
-
Contouring variation affects estimates of normal tissue complication probability for breast fibrosis after radiotherapy
Breast, Vol. 72
2022
-
Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach
Human Mutation, Vol. 43, Núm. 12, pp. 1921-1944
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications biology, Vol. 5, Núm. 1, pp. 1061
-
No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity
International Journal of Radiation Oncology Biology Physics, Vol. 114, Núm. 3, pp. 494-501
-
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
Lung Cancer, Vol. 166, pp. 228-241
-
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients
Radiotherapy and Oncology, Vol. 176, pp. 127-137
-
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort
eBioMedicine, Vol. 84
-
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Radiotherapy and Oncology, Vol. 168, pp. 75-82
2021
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Nature Communications, Vol. 12, Núm. 1
-
A data science approach for early-stage prediction of Patient's susceptibility to acute side effects of advanced radiotherapy
Computers in Biology and Medicine, Vol. 135
-
Breast cancer risk genes - Association analysis in more than 113,000 women
New England Journal of Medicine, Vol. 384, Núm. 5, pp. 428-439
-
Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity
Radiotherapy and Oncology, Vol. 159, pp. 241-248
-
Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
European psychiatry : the journal of the Association of European Psychiatrists, Vol. 64, Núm. 1, pp. e25
-
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant
Genetics in Medicine, Vol. 23, Núm. 9, pp. 1726-1737
2020
-
A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort
Frontiers in Oncology, Vol. 10
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics, Vol. 52, Núm. 1, pp. 56-73
-
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Genetics in Medicine, Vol. 22, Núm. 10, pp. 1653-1666
-
Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study
Psychological Medicine, Vol. 50, Núm. 11, pp. 1884-1897